Sign up to our newsletter

Hytest looks forward to participating in ADLM 2025 (formerly AACC), taking place July 29–31 in Chicago, USA. Come visit us at Booth #1724 to connect with our team and learn how our antibodies and antigens can support your diagnostic solutions.

We are proud to share that Professor Peter Kavsak has been selected as the recipient of the 2025 IFCC Distinguished Award for Contributions to Cardiovascular Diagnostics, sponsored by Hytest. 

Hytest is excited to announce the launch of its new HIV p24 monoclonal antibodies (MAbs) under Cat. # 3H24. All 7 MAbs--GA12, GA17, GA32, GA34, GA38, GA39, and GA54-- are designed to be used for the development of next-generation HIV p24 antigen immunoassays.  

Hytest is excited to announce the launch of its recombinant HCV NS3 antigen (Cat. # 8HC53)—a high-purity reagent developed as capture or detection material for in vitro immunoassays aimed at the qualitative detection of antibodies to Hepatitis C Virus (HCV).

All Hytest SARS-CoV-2 nucleoprotein (NP) antibodies (Cat. #3CV4), including monoclonal antibodies (MAbs) C706, C524, C518, C715, and C527, target the N-terminal part of the nucleoprotein, specifically the region N47-A173. 

We are proud to sponsor the EFLM Cardiac Marker Award, which recognizes remarkable scientific work in the field of cardiovascular diseases. This award, presented by the European Federation of Laboratory Medicine (EFLM), honors the best original research paper on cardiac marker measurements and cardiovascular risk assessment.

Hytest is a Leading Raw Material Supplier for the IVD Industry over the past 30 years

We are in the process of developing our North American operations to align with the same standards we use in Hytest Finland.

As we celebrate our 30th anniversary, Hytest is proud to offer a special opportunity to our valued customers.

Celebrating Excellence in Cardiovascular Diagnostics: Hytest Sponsors IFCC Distinguished Award

May is Cancer Survivor Month. We honor the strength, resilience, and courage of cancer survivors around the world.

We are excited to announce the launch of a new recombinant Glial Fibrillary Acidic Protein (GFAP) antigen, Cat# 8G47.

Hytest is pleased to announce the addition of recombinant monoclonal antibodies RC3A6 and RC8E2 (Cat. # 2I1) to our Insulin product portfolio.

Our monoclonal antibodies (MAbs) can recognize up to 16 different strains of the influenza A virus. 

Meet HyTest team at the China Association of Clinical Laboratory Practice Expo!

Launch of HyTest’s latest monoclonal antibodies targeting the nucleoprotein of influenza B virus!